Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in Nor... ( SAN DIEGO and OSAKA Japan Sept. 2 /- ...)

Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America

Date:9/2/2010

SAN DIEGO and OSAKA, Japan, Sept. 2 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (TSE: 4502), today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

Contrave is a combination therapy believed to address both biological and behavioral drivers of obesity. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior. Orexigen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave on March 31, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

Under the terms of the agreement, Orexigen will receive an upfront cash payment of $50 million from Takeda, and Takeda will obtain an exclusive marketing right from Orexigen in the United States, Mexico and Canada while Orexigen retains the right to co-promote with Takeda in the United States. Orexigen will be eligible to receive payments of over $1 billion upon achieving certain regulatory and sales-based milestones. Assuming Contrave is commercialized, Takeda will pay tiered double-digit royalty payments on net sales in the Territory.

Under the terms of the agreement, Orexigen and Takeda will work together on ongoing development of the product, with Orexigen leading pre-approval activities, and Takeda leading post-approval activities. The parties will share in the costs of any future development of the product.

"Takeda is an ideal partner for Contrave given its proven track record in commercializing innovative medicines and its commitment to the treatment of
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
3. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
6. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
8. BioMarin Acquires ZyStor Therapeutics, Inc.
9. Nile Therapeutics Reports 2010 Second Quarter Financial Results
10. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
11. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept

Post Your Comments:

(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer"). On 20 May 2013, Royalty Pharma ...

(Date:5/23/2013)... WASHINGTON , May 23, 2013 Vanda Pharmaceuticals Inc. ... company has been named the 2013 Life Science Firm of ... (TCM). Vanda was honored at the TCM,s 25 ... Bethesda , Maryland. The Tech Awards Celebration recognizes the ... in Maryland and the surrounding regions. ...

(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering. A portion of the proceeds will be used ...

Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4

[0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [0] Nephros Announces Completion of Rights Offering

... Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today ... antibiotics in two Phase 3 clinical trials exploring the ... adult patients with Clostridium difficile -associated diarrhea (CDAD) ... Clinical Infectious Diseases (CID). The analysis found ...

... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading China-based advanced ... unaudited financial results for the first ... ("1Q FY2011") today.1 Q FY20 ...

Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin China Medical Technologies Reports First Fiscal Quarter Financial Results

(Date:5/24/2013)... KC and Monica Craichy, Founders of ... Their oldest sons, Kyle and Austin Craichy, will be kiteboarding ... several professional kiteboarders. , KC Craichy said he is excited ... come together such that virtually everyone who planned to be ... kite boarders will meet at Matheson Hammock Park and Beach ...

(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...

(Date:5/24/2013)... Denver, CO (PRWEB) May 24, 2013 ... SEO analysis, in partnership with JD Media Surge, a ... , The dental SEO analysis service will focus ... high in the search engines for their competitive keywords. ... the dentists website and recommendations based on what their ...

(Date:5/24/2013)... 24, 2013 Gift Card Network ... competitors in sustainable card material, are combining forces ... materials as a sustainable gift card substrate. , ... industry challenges and increase education and usage of ... support the reduction of carbon footprint and environmental ...

(Date:5/24/2013)... 24, 2013 Started in 1982, AMTC’s SHINE ... Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ministry ... supermodel Millie Lewis and her daughter, Carey Lewis Arban. , ... casting directors, and music professionals including the New York Film ... Media. They are kings of Hollywood and Christian casting directors. ...

Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2 Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3 Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2

[0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes [0] Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge [0] Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants [0] AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013

... studies that was presented yesterday at Digestive Disease Week? ... compounds can sustain relief for these patients with symptoms ... to review the therapeutic benefits for irritable bowel syndrome ... of the bowel disorders like IBS and Crohn's disease ...

... surgeon Dr Jerome Blanchard who had removed the wrong kidney ... , ,The disciplinary hearing was told yesterday that ... a patient and left her dependent on dialysis, as he ... Blanchard took out his patient’s transplant kidney, which was still ...

... says that each time an elderly person falls at ... two days of crew time.// ,Significant numbers ... suggesting that these facilities are relying on ambulance services ... calls for falls made to the ambulance service in ...

... on 100 soft drinks and beverages by the FDA (Food ... the presence of benzene//, a carcinogen in much higher amount ... ,FDA had alerted these companies, and they had ... done so. Though environmental companies had expressed concern regarding this, ...

... facility for the Medical Linear Accelerator (LINAC) here under ... (DIT). ,The Society for Applied Microwave Electronics ... which pioneered the development of an indigenous Medical LINAC, ... a cost of Rs 24.88 crore, DIT Secretary D ...

... such as gastric bypass and laparoscopic reflux ... reflux// disease respectively, are becoming popular, highlights ... Week, which represents the largest gathering of ... such as gastroenterology, endoscopy, gastrointestinal surgery and ...

Cached Medicine News:Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 2 Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 3 Health News:Consultant Bungles A Kidney Surgery 2 Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2 Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3 Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 2 Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 3

New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders Consultant Bungles A Kidney Surgery Ambulance Services Cost ?145 Each Time An Elderly Person Sustains A fal Soda Drinks Contain Benzene - A Carcinogen, Reports FDA Medical LINAC Machine Manufacturing Unit At Khargar Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Vitamin E, Serum or Plasma Vitamin D, 25-Hydroxy Vitamin B12 & Folate Vitamin B6 (Pyridoxine), Total, Plasma